Stefan Zeuzem1. 1. Medical Clinik I, Department of Internal Medicine, J.W. Goethe University Hospital, Frankfurt/Main.
Abstract
BACKGROUND: Among patients with chronic hepatitis C, 20-30% develop hepatic cirrhosis and its complications within 30 years. The antiviral treatment of hepatitis C, previously interferon-based, has recently become inter - feron-free, with resulting improvements in sustained virological response rates, safety, and tolerability and a shorter duration of treatment. METHODS: This review is based on relevant publications retrieved by a selective literature search, and particularly on studies and reviews concerning the course and treatment of hepatitis C. RESULTS: The available drugs for interferon-free antiviral treatment of hepatitis C include inhibitors of the RNAdependent RNA polymerase, NS3/4A protease, and NS5A protein of the hepatitis C virus (HCV), and ribavirin. Typically, two specific inhibitors are given in combination; the usual duration of treatment is 12 weeks.The antiviral drugs differ in their genotypic antiviral effectiveness and resistance barriers. The appropriate drug(s) should be chosen in consideration of the patient's hepatic and renal function and potential drug interactions. These drugs are safe and well-tolerated and result in sustained virological response rates between 90% and 100%. CONCLUSION: All patients with hepatitis C, whatever their disease stage, can derive a sustained eradication of HCV from a combination of drugs with direct antiviral activity. Viral eradication is associated with a better quality of life and with lower morbidity and mortality.
BACKGROUND: Among patients with chronic hepatitis C, 20-30% develop hepatic cirrhosis and its complications within 30 years. The antiviral treatment of hepatitis C, previously interferon-based, has recently become inter - feron-free, with resulting improvements in sustained virological response rates, safety, and tolerability and a shorter duration of treatment. METHODS: This review is based on relevant publications retrieved by a selective literature search, and particularly on studies and reviews concerning the course and treatment of hepatitis C. RESULTS: The available drugs for interferon-free antiviral treatment of hepatitis C include inhibitors of the RNAdependent RNA polymerase, NS3/4A protease, and NS5A protein of the hepatitis C virus (HCV), and ribavirin. Typically, two specific inhibitors are given in combination; the usual duration of treatment is 12 weeks.The antiviral drugs differ in their genotypic antiviral effectiveness and resistance barriers. The appropriate drug(s) should be chosen in consideration of the patient's hepatic and renal function and potential drug interactions. These drugs are safe and well-tolerated and result in sustained virological response rates between 90% and 100%. CONCLUSION: All patients with hepatitis C, whatever their disease stage, can derive a sustained eradication of HCV from a combination of drugs with direct antiviral activity. Viral eradication is associated with a better quality of life and with lower morbidity and mortality.
Authors: Hélène Fontaine; Arnaud Lazarus; Stanislas Pol; Caroline Pecriaux; François Bagate; Philippe Sultanik; Estelle Boueyre; Marion Corouge; Vincent Mallet; Anaïs Vallet-Pichard; Philippe Sogni; Denis Duboc Journal: N Engl J Med Date: 2015-11-05 Impact factor: 91.245
Authors: Edward J Gane; Christian Schwabe; Robert H Hyland; Yin Yang; Evguenia Svarovskaia; Luisa M Stamm; Diana M Brainard; John G McHutchison; Catherine A Stedman Journal: Gastroenterology Date: 2016-05-27 Impact factor: 22.682
Authors: Jordan J Feld; Christophe Moreno; Roger Trinh; Edward Tam; Stefan Bourgeois; Yves Horsmans; Magdy Elkhashab; David E Bernstein; Ziad Younes; Robert W Reindollar; Lois Larsen; Bo Fu; Kevin Howieson; Akshanth R Polepally; Andreas Pangerl; Nancy S Shulman; Fred Poordad Journal: J Hepatol Date: 2015-10-22 Impact factor: 25.083
Authors: Peter Ferenci; David Bernstein; Jacob Lalezari; Daniel Cohen; Yan Luo; Curtis Cooper; Edward Tam; Rui T Marinho; Naoky Tsai; Anders Nyberg; Terry D Box; Ziad Younes; Pedram Enayati; Sinikka Green; Yaacov Baruch; Bal Raj Bhandari; Florin Alexandru Caruntu; Thomas Sepe; Vladimir Chulanov; Ewa Janczewska; Giuliano Rizzardini; Judit Gervain; Ramon Planas; Christophe Moreno; Tarek Hassanein; Wangang Xie; Martin King; Thomas Podsadecki; K Rajender Reddy Journal: N Engl J Med Date: 2014-05-04 Impact factor: 91.245
Authors: Zobair M Younossi; Maria Stepanova; Jordan Feld; Stefan Zeuzem; Ira Jacobson; Kosh Agarwal; Christophe Hezode; Fatema Nader; Linda Henry; Sharon Hunt Journal: J Hepatol Date: 2016-03-05 Impact factor: 25.083
Authors: Edward Gane; Fred Poordad; Stanley Wang; Armen Asatryan; Paul Y Kwo; Jacob Lalezari; David L Wyles; Tarek Hassanein; Humberto Aguilar; Benedict Maliakkal; Ran Liu; Chih-Wei Lin; Teresa I Ng; Jens Kort; Federico J Mensa Journal: Gastroenterology Date: 2016-07-25 Impact factor: 22.682
Authors: Jürgen K Rockstroh; Mark Nelson; Christine Katlama; Jay Lalezari; Josep Mallolas; Mark Bloch; Gail V Matthews; Michael S Saag; Philippe J Zamor; Chloe Orkin; Jacqueline Gress; Stephanie Klopfer; Melissa Shaughnessy; Janice Wahl; Bach-Yen T Nguyen; Eliav Barr; Heather L Platt; Michael N Robertson; Mark Sulkowski Journal: Lancet HIV Date: 2015-07-09 Impact factor: 16.070
Authors: Mark S Sulkowski; David F Gardiner; Maribel Rodriguez-Torres; K Rajender Reddy; Tarek Hassanein; Ira Jacobson; Eric Lawitz; Anna S Lok; Federico Hinestrosa; Paul J Thuluvath; Howard Schwartz; David R Nelson; Gregory T Everson; Timothy Eley; Megan Wind-Rotolo; Shu-Pang Huang; Min Gao; Dennis Hernandez; Fiona McPhee; Diane Sherman; Robert Hindes; William Symonds; Claudio Pasquinelli; Dennis M Grasela Journal: N Engl J Med Date: 2014-01-16 Impact factor: 91.245
Authors: Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245
Authors: Marcus-Alexander Wörns; Peter Robert Galle; Stefan Zeuzem; Peter Schirmacher; Michael Manns; Arndt Vogel Journal: Dtsch Arztebl Int Date: 2017-09-04 Impact factor: 5.594
Authors: Georg Dultz; Tobias Müller; Jörg Petersen; Stefan Mauss; Tim Zimmermann; Marion Muche; Karl-Georg Simon; Thomas Berg; Stefan Zeuzem; Dietrich Hüppe; Klaus Böker; Heiner Wedemeyer; Tania M Welzel Journal: Drugs Aging Date: 2018-09 Impact factor: 4.271